4-1BB transcriptomic expression patterns across malignancies:Implications for clinical trials of 4-1BB agonists
作者机构：Department of Thoracic Oncology and Respiratory MedicineTokyo Metropolitan Cancer and Infectious Diseases CenterKomagome HospitalTokyoJapan Department of Precision Cancer MedicineCenter for Innovative Cancer TreatmentTokyo Medical and Dental UniversityTokyoJapan Center for Personalized Cancer Therapy and Division of Hematology and OncologyDepartment of MedicineUniversity of California San DiegoMoores Cancer CenterLa JollaCaliforniaUnited States Dartmouth Cancer CenterHematology and Medical OncologyLebanonNew HampshireUnited States Labcorp OncologyDurhamNorth CarolinaUnited States OmniSeq IncorporationBuffaloNew YorkUnited States Division of Surgical OncologyDepartment of SurgeryCenter for Personalized Cancer TherapyUniversity of California San DiegoLa JollaCaliforniaUnited States Medical College of Wisconsin Cancer Center and Genomic Sciences and Precision Medicine CenterMedical College of WisconsinMilwaukeeWisconsinUnited States Department of OncologyMedical College of Wisconsin Cancer CenterMilwaukeeWisconsinUnited States Department of OncologyUniversity of NebraskaOmahaNebraskaUnited States
出 版 物：《Cancer Communications》 (癌症通讯（英文）)
年 卷 期：2024年第44卷第10期
页 面：1168-1172页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：4-1BB,a member of the tumor necrosis factor receptor superfamily,is an important co-stimulatory molecule regulating the activity of immune cells across a range of physiological and pathological processes,which culminates in a potent immune response(Figure 1A and B)[1,2].Numerous clinical trials have been conducted utilizing 4–1BB agonists(Supplemental Table S1);however,previous and ongoing 4-1BB agonist trials are being conducted without biomarker selection,which potentially explains their modest ***,several studies suggest the potential value of utilizing transcriptomics in addition to genomics to identify the unique immunologic signature of individual tumors[3–7].
维普期刊数据库